A Retrospective Study of Erlotinib in the Treatment of 70 Patients with Non-small Cell Lung Cancer.

Erlotinib is a small molecular inhibitor of tyrosine kinase. Multiple foreign and demestic studies have confirmed that it can prolong the median progression-free survival time (PFS) and the overall survival (OS), which could be more significant in the selected population. In this study we retrospect...

Full description

Saved in:
Bibliographic Details
Published in:Zhongguo fei ai za zhi 2009-12, Vol.12 (12), p.1309-1311
Main Authors: Wu, Yuhua, Tao, Hong, Tang, Junfang, Zhang, Xinyong, Zhu, Yunzhong, Liu, Zhe, Shi, Heling, Meng, Qiyi, Wu, Wei, Liu, Zan, Guo, Lili, Li, Mingzhi, Xu, Liyan
Format: Article
Language:Chinese
Subjects:
Erlotinib
Lung neoplasms
Treatment outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Erlotinib is a small molecular inhibitor of tyrosine kinase. Multiple foreign and demestic studies have confirmed that it can prolong the median progression-free survival time (PFS) and the overall survival (OS), which could be more significant in the selected population. In this study we retrospectively oberserved the response, the survival and adverse reaction of erlotinib in non-selected non-small cell lung cancer. The retrospective study included seventy non-small-cell lung cancer patients, who were treated with erlotinib from July 2005 to July 2009. Erlotinib was prescribed at a dose of 150 mg daily. Sixty-eight patients were evaluated response. Among these patients, CR 0 case, PR 26 cases, RR (CR+PR) 38.2% and SD 24 cases as their best response, disease control rate (DCR=CR+PR+SD) 73.5%, PD 18 cases (26.5%). Sixty-three patients were evaluated PFS. The median PFS was 3.0 months. The median PFS of adenocarcinoma and non-adenocarcinoma was 3.0 months vs 2.6 months. The drug-related adverse reactions were
ISSN:1009-3419
1999-6187
DOI:10.3779/j.issn.1009-3419.2009.12.18